DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Dry/Wet Age-Related Macular Degeneration (US) 2013

BioTrends Research Group is pleased to announce the continuation of TreatmentTrends®: Dry/Wet Age-Related Macular Degeneration (US) in 2013. In this report, current trends in the management of both dry and wet age-related macular degeneration (AMD) are explored from the perspective of retinal specialists and general ophthalmologists.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They offer insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Understand the relative wet and dry AMD patient load by disease characteristics

  • Understand product attributes that are most important to retinal specialists and ophthalmologists when selecting AMD therapy and compare the different agents on how they are perceived to perform against each attribute

  • Understand how the use of each treatment approach and each agent is expected to change in the next six months and what factors are driving those trends

  • Evaluate sales and messaging efforts of marketed wet AMD therapies

  • Assess awareness of and interest in therapies that are in late stage development for the treatment of AMD


Sample Frame & Methodology:

- ~80 fellowship-trained retinal specialists and ~20 general ophthalmologists complete a 45-minute online quantitative survey with several open ended questions for qualitative feedback

To qualify, respondents must meet the following criteria:

- Minimum of 50 wet AMD patients under their personal management

- Personally administer intravitreal injections to their patients with wet AMD

- Have been in practice a minimum of 2 years and a maximum of 35 years

- More than 75% of professional time spent in clinical practice


- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Related 2013 Reports:

- ChartTrendsĀ®: Wet AMD (US)

- TreatmentTrendsĀ®: Dry/Wet AMD (EU)

- TreatmentTrendsĀ®: Diabetic Retinopathy and Diabetic Macular Edema (US)